Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview
Cancer Reports · 2026
DOI: 10.1002/cnr2.70450 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Yufeng Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospit…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Central Guidance on Local Science and Technology Development Fund of Liaoning Province.
Abstract (Originalsprache)
Background
Refractory/relapsed acute myeloid leukemia (R/R‐AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the primary treatment option in such patients. However, posttransplant relapse is still a challenge, with no established effective regimens. Case In this case report, we present the case of a 40‐year‐old male diagnosed with R/R‐AML who underwent salvage allo‐HSCT. Unfortunately, after 4 months of follow‐up, a relapse occurred. We modified the immunosuppressive therapy and administered donor lymphocyte infusion (DLI) and decitabine but failed to obtain complete remission (CR). Subsequently, a combination of venetoclax (Ven) and azacitidine (Aza), followed by the DLI regimen, was initiated. The patient achieved CR with no measurable residual disease.
Conclusion
Our data suggest that the administration of Ven in combination with Aza followed by the DLI regimen used for early post‐HSCT relapsed AML could serve as a valuable reference for treating similar patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.
- Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Medical University, Dalian, China.
- School of Public Health, Dalian Medical University, Dalian, China.
- Department of Pediatrics, Pediatric Oncology and Hematology Center, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
ORCID-Profile: Yufeng Du, Mohammad Arian Hassani, Zhijia Zhao, Chengtao Zhang, Jinsong Yan
Förderung
- Central Guidance on Local Science and Technology Development Fund of Liaoning Province
Zitieren
APA
Du, Y., Hassani, M. A., Li, C., Zhao, Z., Liu, Y., Zhang, C., & Yan, J. (2026). Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview. Cancer Reports. https://doi.org/10.1002/cnr2.70450
Vancouver
Du Y, Hassani MA, Li C, Zhao Z, Liu Y, Zhang C, et al. Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview. Cancer Reports. 2026. doi:10.1002/cnr2.70450
BibTeX
@article{Du2026,
author = {Du, Yufeng and Hassani, Mohammad Arian and Li, Chunhong and Zhao, Zhijia and Liu, Yikun and Zhang, Chengtao and Yan, Jinsong},
title = {Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70450}
}
EUVIMED